GHR
Growth hormone receptor
As of the edition of 20 October 2026, GHR (growth hormone receptor, UniProt P10912) has 11 drugs tested at it and 21 companies on the list, 2 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10912
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 9
- Disease areas
- Hormones; Bones, joints and muscles; Nervous system; Inherited and neonatal; Urinary and reproductive; Nutrition and metabolism; Pregnancy and women's health; Heart and blood vessels
- Registered trials of its drugs
- 379
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Somatropin | Marketed | Phase 4 | Ended 2003 |
| Pegvisomant | Marketed | Phase 4 | Ended 2015 |
| Somapacitan | Marketed | Phase 3 | Ends 2032 |
| Somatrogon | Marketed | Phase 3 | Ends 2035 |
| Lonapegsomatropin | Marketed | Phase 3 | Ends 2033 |
| ACP-001 | Went quiet | Phase 2 | none listed |
| Cimderlirsen sodium | Status not established | Phase 2 | none listed |
| MAR002 | Active | Phase 2 | none listed |
| ALTU-238 | Went quiet | Phase 2 | none listed |
| ALXN2420 | Stopped | Phase 2 | none listed |
| Somatrem | Marketed | No phase stated | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 5 |
| Engaged | 12 |
| Undetermined | 2 |
| Total on the list | 21 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Merck & Co. | Route B |
| Novo Nordisk | Route B |
The other 18 companies at GHR
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at GHR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.